Phillip Capital Research

Peer Groups

Malaysia

Home >> Country >> Malaysia >> Company

Latest Reports
Date	Description	Country	Analyst	Download

24-Sep-2021	Despite recent share price weakness, Dpharma, being the largest generic drug manufacturer with highest sales volume in Malaysia, remains fundamentally sound and provides a compelling Buy for investors. At 23.4x 2022 PER it is at a discount to its 5-year average PER of 32.9x	Malaysia	Malaysia Research Team
02-Oct-2018	Despite being a small nutraceutical company, Nova’s profit margins are head and shoulder above its peers. Even with expiry of its BioNexus tax exemption status, Nova’s margins remain the highest as bulk of its sales is derived from its house brand as the company has strong in-house R&D capability.	Malaysia	Malaysia Research Team
30-May-2018	“KPJ as it is the largest private hospital operator in Malaysia, which is lauded with positive structural trends ranging from rising ageing population, lifestyle diseases and increasing affluence that will aid and steer organic growth continuously. We think investors with a longer-term investment horizon will be rewarded. Currently it is trading with a prospective PER of 21.9x, which remains at a discount to its 5-year PER of 28.8x and also IHH, which trades at 52.8x.”	Malaysia	Malaysia Research Team
10-Apr-2018	CCM Duopharma Biotech Bhd (“CCMD”) – Enhancing Quality of Life	Malaysia	Malaysia Research Team